The pharmaceutical company specializing in the treatment of disorders of the central system, Neuraxpharm, has signed a commercialization agreement for Mjn-Seras with the startup Mjn-Neuro, a wearable medical device that allows to predict the risk of having an epileptic seizure.
With this agreement, Neuraxpharm increases its offer of comprehensive resources for patients with epilepsy and enters the complementary solutions market. This is a very significant step for the company on its way into the digital health and wearable medical device market.
With a growing demand for patients who are looking for different solutions to cover unmet needs, as well as the simplification by health systems of putting these solutions on the market and making them accessible to everyone, digital health becomes a key element and with a significant potential in CNS care.
The agreement with Mjn-neuro covers all states belonging to the European Union, as well as the United Kingdom, Norway, Iceland, Liechtenstein and Switzerland. Since 2020, mjn-SERAS has had the support and financing of the European Institute of Technology (EIT Health), an organization of the European Union, for the development of the project thanks to the Bridgehead and Start-up Amplifier programs.
In 2018, the project received support from the EU funding program Horizon 2020, created by the European Commission, and also has the participation of a consortium of companies and health professionals.
Dr. Jörg-Thomas Dierks, Chief Executive Officer of Neuraxpharm, commented: “The agreement to commercialize mjn-SERAS is an important step forward in our strategy to offer comprehensive solutions for patients with epilepsy. There is a great unmet medical need for new and innovative solutions to help patients suffering from epilepsy. By entering the digital market, Neuraxpharm can offer further support and explore all that uncovered potential. In the future, we will continue to increase our offer in new digital health solutions for patients suffering from epilepsy and other CNS disorders around the world.”.
David Blánquez, CEO and co-founder of Mjn-neuro, adds: “We are at a great moment in the evolution of mjn-neuro. The agreement signed with Neuraxpharm is an important milestone for our strategy and scalability in the epilepsy market, a sector with great potential. We have a lot in common with Neuraxpharm. We are both companies committed to innovation and digital health as a way to improve the quality of life of people with epilepsy. Therefore, we believe that, together, we will be able to achieve new goals and objectives in the coming years.”.
Advanced help and prevention
Mjn-Seras is a digital health solution that provides advanced help and helps prevent accidents caused by epileptic seizures in drug-resistant patients.
This non-invasive medical device has several sensors that record the electrical activity of the brain in real time and, thanks to artificial intelligence algorithms, its main functionality is to issue a warning when the risk of epileptic seizures is high.
The device received the CE mark for Europe in 2020 from the BSI Group, the prestigious international notified body. The results of the clinical trial are expected to be available in the second half of 2023. It will be the first wearable device that predicts epileptic seizures, giving time to get to a safe place and helping to avoid accidents and injuries.
Epilepsy is a brain disorder characterized by abnormal electrical activity that causes unpredictable seizures, unusual behaviors and sensations, and sometimes loss of consciousness. Such crises can recur several times in a day and can cause accidents and injuries.
In addition to physical impacts, the unpredictability of the medical condition also has a negative impact on mental health. It has been shown that anxiety, stress and depression are prevalent in people with epilepsy.
The disorder negatively affects the quality of life of patients and their social integration, even today they are often stigmatized. Epilepsy is one of the most common chronic disorders of our time and affects more than 50 million people of all age groups.
